Hyperthyroidism is a clinical state characterized by excessive synthesis and secretion of thyroid hormones by the thyroid gland. This metabolic overdrive accelerates bodily processes, presenting clinically as weight loss, heat intolerance, tachycardia, tremors, and anxiety. The primary goal of medical management is to reduce thyroid hormone production, alleviate distressing symptoms, and restore a normal metabolic state without causing permanent hypothyroidism, where possible.
Thioamides are the cornerstone of medical therapy for hyperthyroidism. This drug class includes carbimazole, methimazole, and propylthiouracil (PTU).
Selecting between PTU and methimazole depends on specific patient factors and clinical phases of the disease. Methimazole is generally preferred for long-term management because of its convenient dosing schedule and lower risk of severe liver injury. However, propylthiouracil is the preferred agent during the first trimester of pregnancy to minimize rare fetal abnormalities associated with methimazole. PTU is also favored in treating thyroid storm because of its unique ability to block peripheral T4-to-T3 conversion.
Radioactive iodine (I-131) is administered orally as a capsule or liquid. Once absorbed by the body, it is actively concentrated by the thyroid gland because the follicular cells require iodine to make hormones. The isotope emits beta particles that destroy overactive thyroid tissue locally, gradually shrinking the gland and curing the hyperthyroid state. It is a definitive, non-surgical treatment frequently used in Graves' disease or toxic multinodular goiter. It is strictly contraindicated in pregnancy due to the risk of destroying the fetal thyroid gland.
Beta-blockers like propranolol do not reduce the synthesis of thyroid hormones. Instead, they block beta-adrenergic receptors, rapidly controlling distressing sympathetic symptoms such as palpitations, tremors, anxiety, and tachycardia. Propranolol also provides secondary benefit by partially inhibiting the peripheral conversion of T4 to T3 at higher doses. They serve as a temporary bridge while waiting for thioamides or radioactive iodine to take full effect.
Large doses of iodides, such as Lugol's solution or saturated solution of potassium iodide (SSKI), paradoxically decrease the release of thyroid hormones from the gland—a phenomenon known as the Wolff-Chaikoff effect. This action lasts only temporarily, typically 10 to 14 days, after which the gland escapes the block and may release stored hormone. Consequently, these solutions are reserved for short-term preoperative preparation before a thyroidectomy to reduce vascularity and decrease the risk of intraoperative bleeding.
Antithyroid drugs carry serious potential adverse effects that require diligent nursing vigilance. Agranulocytosis, a severe drop in white blood cells, is a life-threatening complication that presents with fever and sore throat. Hepatotoxicity is another major concern, particularly with propylthiouracil. Nurses must monitor complete blood counts, liver function tests, and baseline thyroid profiles. Patients must be instructed to report signs of infection or jaundice immediately.
In many Nigerian healthcare settings, managing hyperthyroidism involves navigating economic constraints, inconsistent follow-up, and the use of traditional remedies alongside orthodox medicine. Patient education must emphasize adherence to daily medication schedules, recognizing symptoms of drug toxicity, and keeping regular clinic appointments for laboratory tests. Nurses should inquire gently about concurrent herbal preparations to prevent harmful interactions and ensure safe, comprehensive care.